Every Wegovy tablet contains two active stories. There’s semaglutide, the celebrated molecule that mimics a gut hormone and quietly persuades your brain to stop wanting seconds. And then there’s salcaprozate sodium, a compound most patients have never heard of, doing the unglamorous work of ferrying semaglutide through the stomach wall and into the bloodstream. Without it, the pill simply wouldn’t work. Semaglutide, left to its own devices in the acidic chaos of the gut, would be destroyed before it reached circulation.
SNAC, as pharmacologists call it, has been quietly present in oral drug formulations for years. It carries FDA approval, holds “generally regarded as safe” status, and until recently attracted little scientific scrutiny of its own.
Now a team at the University of South Australia has done something no one had done before: tracked what happens to the gut when SNAC is swallowed repeatedly, day after day, over three weeks. What they found is not proof of harm. But it’s the kind of finding that makes you wonder what else might be travelling along for the ride, and what it might be doing while it’s there. Amin Ariaee, a PhD researcher in the School of Pharmacy and Biomedical Sciences, and his colleagues gave rats daily doses of SNAC alone, semaglutide alone, or the combination, then examined their gut microbiota, liver, faecal chemistry, and blood for markers of inflammation. The doses were calculated to approximate human therapeutic exposures.
The microbiota results were striking. Not in the way scientists usually worry about.
SNAC didn’t reduce the sheer number of microbial species, the metric researchers typically use to gauge gut health. Overall diversity held steady. What shifted, significantly, was the composition, the balance of who’s living down there and what they’re doing. Two families of bacteria that ferment dietary fibre and produce protective short-chain fatty acids, Muribaculaceae and Bacteroidaceae, were depleted by 62 per cent and 77 per cent respectively in the SNAC-only group compared with controls. Meanwhile Desulfovibrionaceae, a family associated with inflammatory conditions, expanded roughly sevenfold. Faecal butyrate, the fatty acid that feeds the cells lining the colon and keeps the gut wall intact, fell by 77 per cent.
Here’s the problem with butyrate disappearing. It’s not just a fuel molecule; it’s structural. Colonocytes (the cells that form the gut lining) depend on it to maintain the tight junctions that stop unwanted compounds leaking from gut to bloodstream. When butyrate falls, those junctions weaken. Bacterial products, including lipopolysaccharides from the cell walls of gut microbes, can slip through into the portal circulation and reach the liver. That may explain another of the study’s findings: SNAC-treated rats showed a 12.9 per cent increase in liver weight and a 30 per cent reduction in caecum mass, the intestinal chamber where most microbial fermentation happens. Neither change was seen in rats given semaglutide alone.
Plasma cytokine readings added another layer. TNF-alpha, a central marker of systemic inflammation, was elevated by 70 per cent in the SNAC group. Animals given the semaglutide-SNAC combination showed a 25 per cent rise in interleukin-6 and, more unexpectedly, an 85 per cent suppression of brain-derived neurotrophic factor, a protein involved in neuroplasticity and cognitive function. Ariaee is careful about what to make of that last finding. “While SNAC enables semaglutide to be taken as a tablet,” he says, “our study found that it was also associated with shifts in potentially harmful gut bacteria, elevated inflammatory markers and depletion of proteins linked to cognitive impairment. These findings warrant further investigation.”
The mechanism the team proposes runs something like this. Most of the SNAC swallowed never actually makes it across the stomach. Oral semaglutide achieves only 0.4 to 1 per cent bioavailability; the rest of the drug is lost, and the SNAC that enabled it to work passes, largely intact, into the small intestine and colon. There, its membrane-disrupting properties, which in the stomach serve to open pathways for drug absorption, may continue to act on the densely colonised microbial communities in the lower gut. SNAC essentially has a second career downstream, one nobody designed it for.
None of this means the pills are dangerous. Paul Joyce, the study’s senior author, is precise about the limits of what the data show. “Our findings do not prove that SNAC causes harm in humans,” he says. “However, they do show that the ingredient enabling these tablets to work may have adverse biological effects beyond drug absorption.” The study used healthy rats, not humans, not people with obesity or diabetes. Six animals per group is a small sample. The 21-day window is enough to capture microbiota restructuring but not to say whether the changes persist or reverse when treatment stops.
What the study does do is close an odd gap. SNAC has been used in oral supplements for vitamin B12 for years. It’s well-established. But it’s never been systematically scrutinised in an in vivo model for its effects on the gut ecosystem, which is, by any reasonable measure, a significant knowledge gap for a compound now entering daily long-term use in the hundreds of millions.
Obesity affects roughly one in eight people globally. In the United States, 43 per cent of adults live with the condition. The FDA approved an oral Wegovy tablet late last year, with expectations that its convenience will expand an already growing market for GLP-1 therapies substantially. “These medicines are typically taken daily and often for long periods,” says Joyce. “As their use expands globally, it becomes increasingly important to evaluate all components of these therapies, not just the active compound.”
The researchers are calling for longer studies, disease models, and direct measurements of intestinal permeability to establish whether the observed correlations reflect genuine biological harm. In the meantime, pharmaceutical formulators are beginning to explore what they’re calling microbiome-active drug delivery systems, alternative approaches to oral peptide delivery designed to achieve gastric absorption without disturbing the microbial communities further along the digestive tract. Whether that effort bears fruit soon enough to matter for the current generation of oral GLP-1 drugs remains to be seen. SNAC is, for now, doing its job. The question researchers are now asking is whether it’s doing anything else besides.
Study link: https://pdf.sciencedirectassets.com/271103/1-s2.0-S0168365926X20016/1-s2.0-S0168365926001136/main.pdf
ScienceBlog.com has no paywalls, no sponsored content, and no agenda beyond getting the science right. Every story here is written to inform, not to impress an advertiser or push a point of view.
Good science journalism takes time — reading the papers, checking the claims, finding researchers who can put findings in context. We do that work because we think it matters.
If you find this site useful, consider supporting it with a donation. Even a few dollars a month helps keep the coverage independent and free for everyone.